ANNOVIS BIO, INC. RECEIVES CONTINUED LISTING STANDARD NOTICE FROM THE NYSE
Annovis Bio, Inc. (ANVS) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ANNOVIS BIO, INC. RECEIVES CONTINUED LISTING STANDARD NOTICE FROM THE NYSE MALVERN, PA – October 30, 2026 – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntan
How this was made
The 30-second read
Why it matters
The listing notice does not affect operations but creates regulatory and liquidity risk, likely prompting short sellers and cautious investors.
Market read
The notice is a primary disclosure that could materially affect ANVS price due to delisting risk.
What to watch
Potential for a private placement or reverse split to restore compliance, which could mitigate downside if executed promptly.
Background
Annovis Bio is a Phase 3 clinical‑stage biotech developing buntanetap for neurodegenerative diseases. Its market cap fell below $50 million, triggering NYSE standards.
Ticker impact
Annovis Bio received a NYSE continued listing notice due to market cap and equity below required thresholds.
likely downward pressure as investors price in compliance uncertainty and possible suspension.
A listing deficiency notice is a material corporate action that often triggers sell‑offs, especially for a micro‑cap biotech with limited liquidity.
Market effects
May raise scrutiny on other small‑cap biotech listings and could tighten NYSE compliance monitoring.
Limited to U.S. exchange‑listed micro‑caps; no broader regional effect.
Minimal global impact; primarily a company‑specific compliance issue.
Counterpoint
If the company quickly submits a credible cure plan, the notice could be priced out, offering a short‑term buying opportunity on a bounce.
Key entities
- companyAnnovis Bio, Inc.
Biotech firm facing NYSE continued listing deficiency.
- exchangeNew York Stock Exchange
Issuer of the continued listing notice.
